Clinical trials
Bacteremia clinical trials
Below are recruiting bacteremia clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06135350RecruitingPhase 2
Preventing infections in ICU patients on ventilators
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
Moscow, MoscowAges 18 years+ - NCT06874920Enrolling by invitation
Antibiotic choice based on hospital lab reports in transplant patients with bloodstream infection
This study looks at whether choosing antibiotics based on local hospital lab reports (antibiograms) works well for organ transplant patients who have a single bacteria in their bloodstream. It hopes to find the best way to treat these infections.
MilanAges 18 years+ - NCT06853301Recruiting
A faster test to find bloodstream infections
This study tests a new machine learning method to quickly identify bacteria in the blood using special sample bottles. If you are getting blood cultures done already, this may help get results faster.
GrenobleAges 18 years+ - NCT06838598Recruiting
Studying biofilm on arterial catheters in the ICU
This study looks at the buildup of bacteria on arterial catheters (thin tubes placed in an artery) used in intensive care. By understanding these biofilms, doctors may find better ways to prevent infections.
Dijon, Bourgogne-Franche-ComtéAges 18 years+ - NCT06833593Recruiting
Antibiotic combinations for enterococcus blood infection
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
Bologna, BolognaAges 18 years+ - NCT06821282Recruiting
Tracking antibiotic resistance in the DRC
This study looks for antibiotic-resistant bacteria in the blood of patients with a suspected bloodstream infection. The goal is to understand which antibiotics still work, helping doctors choose the right treatment.
Kinshasa, Kinshasa CityAges 6 months+ - NCT05922124RecruitingPhase 4
Testing two antibiotics against resistant lung and bloodstream infections
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
HaifaAges 16 years+ - NCT03671967RecruitingPhase 4
Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Calgary, AlbertaAges 18 years+ - NCT06726395RecruitingPhase 4
Comparing two antibiotics for staph bloodstream infection
This trial compares two antibiotics, cloxacillin and benzylpenicillin, to see which works better for patients with a bloodstream infection caused by a specific type of staph bacteria that responds well to penicillin. It may help guide more effective treatment.
LundAges 18 years+ - NCT06650488RecruitingPhase 4
Clopidogrel vs aspirin after staph bloodstream infection
This trial compares two blood-thinning medicines, clopidogrel and aspirin, to see which better prevents heart attacks and strokes in people who have had a staph infection in their blood. If you already take aspirin for heart or blood vessel problems, this study may help find the safest way to protect your heart.
St. John's, Newfoundland and LabradorAges 18 years+ - NCT06537609Recruiting
Testing treatments for Gram-negative bloodstream infections
This trial tests different ways to treat infections in the blood caused by Gram-negative bacteria. It looks at whether reducing antibiotics, switching to pills, or managing central lines improves outcomes while keeping you safe.
Kogarah, New South WalesAges birth–130 years - NCT06457386Recruiting
Echocardiogram vs no echocardiogram for low-risk Staph blood infection
This study compares two approaches for people with a blood infection caused by Staphylococcus aureus who are at low risk for heart infection (VIRSTA score <3). Half of the participants will get a standard echocardiogram (heart ultrasound), and the other half will not, to see if skipping the test is safe and effective.
ParisAges 18 years+ - NCT05975671Recruiting
Survey in pediatric ICU to reduce upfront vancomycin use
This study is a survey and quality-improvement effort in participating children’s intensive care units. It aims to understand and change how doctors decide to start vancomycin (an antibiotic) when sepsis is suspected, to improve care and avoid unnecessary use.
Atlanta, GeorgiaAges Any age - NCT06368388Recruiting
Personalized phage therapy for hard-to-treat infections
This trial studies using phages (viruses that attack bacteria) to treat infections that have not improved with other treatments. It aims to see if this patient-specific approach works and what it costs.
LeuvenAges Any age - NCT06080698Recruiting
Oral antibiotics for bloodstream infection trial
This trial tests whether switching from IV to oral antibiotics is just as effective for treating Gram-negative bloodstream infections. If you qualify, you may receive either continued IV antibiotics or switch to pills, with follow-up on your recovery and quality of life.
San Francisco, CaliforniaAges 18 years+ - NCT05770622RecruitingPhase 4
Vancocin dosing check in young infants with infections
This trial studies a better way to monitor and adjust vancomycin (an antibiotic) dosing in very young infants. It may help your baby get the right dose while reducing the risk of under- or over-dosing.
Melbourne, VictoriaAges birth–3 months - NCT05721781Recruiting
Reducing infection risk after gum and tooth issues
This study looks at ways to lower the risk of infective endocarditis, a serious heart infection that can happen after certain bacteria enter the bloodstream from the mouth. You may be asked to pause routine dental cleanings for a period while they track dental health and infection risk.
Boston, MassachusettsAges 18 years+ - NCT05137119RecruitingPhase 4
Adaptive study of treatments for staph bloodstream infection
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
Houston, TexasAges Any age
Hear when a new Bacteremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bacteremia?
- Yes. Clin2 currently lists 42 recruiting bacteremia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bacteremia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bacteremia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.